These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3207433)

  • 1. Ganglioside therapy in experimental diabetic neuropathy.
    Spüler M; Dimpfel W; Tüllner HU
    Arzneimittelforschung; 1988 Jul; 38(7):881-4. PubMed ID: 3207433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gangliosides on nerve conduction velocity during diabetic neuropathy in the rat.
    Spüler M; Dimpfel W; Tüllner HU
    Arch Int Pharmacodyn Ther; 1987 Jun; 287(2):211-23. PubMed ID: 3307667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganglioside therapy in diabetic neuropathy.
    Horowitz SH
    Muscle Nerve; 1986; 9(6):531-6. PubMed ID: 3526143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy.
    Sayyed SG; Kumar A; Sharma SS
    Life Sci; 2006 Jul; 79(8):777-83. PubMed ID: 16581090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of ganglioside therapy for diabetic neuropathy.
    Hallett M; Flood T; Slater N; Dambrosia J
    Muscle Nerve; 1987; 10(9):822-5. PubMed ID: 3683453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counteraction on experimentally induced diabetic neuropathy by levocarnitine acetyl.
    Pacifici L; Bellucci A; Piovesan P; Maccari F; Gorio A; Ramacci MT
    Int J Clin Pharmacol Res; 1992; 12(5-6):231-6. PubMed ID: 1301403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats.
    Zhang W; Kamiya H; Ekberg K; Wahren J; Sima AA
    Diabetes Metab Res Rev; 2007 Jan; 23(1):63-70. PubMed ID: 16845685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor.
    Manschot SM; Gispen WH; Kappelle LJ; Biessels GJ
    Diabetes Metab Res Rev; 2003; 19(6):469-77. PubMed ID: 14648806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats.
    Nangle MR; Gibson TM; Cotter MA; Cameron NE
    Planta Med; 2006 May; 72(6):494-500. PubMed ID: 16773532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy.
    Saini AK; Kumar H S A; Sharma SS
    Eur J Pharmacol; 2007 Jul; 568(1-3):164-72. PubMed ID: 17521626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganglioside treatment of neuropathy in diabetic mice.
    Norido F; Canella R; Gorio A
    Muscle Nerve; 1982 Feb; 5(2):107-10. PubMed ID: 7070391
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy.
    Sharma SS; Sayyed SG
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1022-8. PubMed ID: 17042909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electromyographic study of diabetic and alcoholic polyneuropathic patients treated with gangliosides.
    Bassi S; Albizzati MG; Calloni E; Frattola L
    Muscle Nerve; 1982; 5(5):351-6. PubMed ID: 6289096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits.
    Pop-Busui R; Sullivan KA; Van Huysen C; Bayer L; Cao X; Towns R; Stevens MJ
    Exp Neurol; 2001 Apr; 168(2):259-72. PubMed ID: 11259114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of diabetic neuropathy in the C57BL/Ks (db/db) mouse and its treatment with gangliosides.
    Norido F; Canella R; Zanoni R; Gorio A
    Exp Neurol; 1984 Feb; 83(2):221-32. PubMed ID: 6692864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy.
    Bordet T; Buisson B; Michaud M; Abitbol JL; Marchand F; Grist J; Andriambeloson E; Malcangio M; Pruss RM
    J Pharmacol Exp Ther; 2008 Aug; 326(2):623-32. PubMed ID: 18492948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in thermal sensation in diabetic patients after treatment with gangliosides.
    Abraham RR; Levy DM; Abraham RM
    Diabetes Res; 1988 Mar; 7(3):129-35. PubMed ID: 3046820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coenzyme Q(10) and alpha-lipoic acid supplementation in diabetic rats: conduction velocity distributions.
    Ayaz M; Tuncer S; Okudan N; Gokbel H
    Methods Find Exp Clin Pharmacol; 2008 Jun; 30(5):367-74. PubMed ID: 18806896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated diabetic neuropathy in axons without neurofilaments.
    Zochodne DW; Sun HS; Cheng C; Eyer J
    Brain; 2004 Oct; 127(Pt 10):2193-200. PubMed ID: 15289271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.